SEATTLE, WASHINGTON--(Marketwired - July 25, 2013) - Ventripoint Diagnostics (TSX VENTURE:VPT)(OTCQX:VPTDF) is pleased to announce that the cardiology group from the University of Chicago, led by Dr. Roberto Lang, has published a paper entitled "Three-Dimensional Modeling of the Right Ventricle from Two-Dimensional Transthoracic Echocardiographic Images: Utility of Knowledge-Based Reconstruction* in Pulmonary Arterial Hypertension" in the Journal of the American Society of Echocardiography, Volume 26, Issue 8, Pages 860-867, August 2013. 

The paper concludes: "Three-dimensional reconstruction of the RV endocardium from 2D transthoracic echocardiographic images obtained in patients with Pulmonary Arterial Hypertension (PAH), as accomplished by Knowledge-Based Reconstruction (KBR), is feasible, accurate, and reproducible."

"We congratulate the Chicago cardiology team on the publication of this first-in-humans, clinical study in the premiere journal in the field of echocardiography," stated Dr. George Adams, CEO of Ventripoint.

*KBR is the scientific terminology for Ventripoint's VMS™ product. The VMS™ is for investigational use only in the United States and approved for clinical use in Canada and Europe.

About the Journal of the American Society of Echocardiography

The Journal of the American Society of Echocardiography (JASE) is the official publication of the American Society of Echocardiography, which is the largest international organization for cardiac imaging. JASE brings physicians and sonographers the very latest clinical, scientific, legal, and economic information regarding the use of cardiac ultrasound. The Journal's original, peer-reviewed articles cover conventional procedures as well as newer clinical techniques. JASE has a 2012 Impact Factor of 4.3.

About Ventripoint Diagnostics Ltd.

Ventripoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children and adults, pulmonary arterial hypertension and left-heart failure are the first applications in a suite of applications for all major heart diseases - a multi-billion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of Ventripoint's VMS™ tool and the company is pursuing the U.S. FDA marketing clearance through the 510(k) process.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.